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Abstract
Background Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been based on retrospective case 
series. The results of six randomized clinical trials including five different monoclonal antibodies targeting four molecules 
and three distinct pathophysiological pathways have recently been published.
Methods Literature search on clinical trials and case studies in NMOSD up to July 10. 2020.
Results We review mechanism of action, efficacy and side effects, and consequences for reproductive health from tradi-
tional immunosuppressants and monoclonal antibodies including rituximab, inebilizumab, eculizumab, tocilizumab and 
satralizumab.
Conclusion In NMOSD patients with antibodies against aquaporin 4, monoclonal antibodies that deplete B cells (rituxi-
mab and inebilizumab) or interfere with interleukin 6 signaling (tocilizumab and satralizumab) or complement activation 
(eculizumab) have superior efficacy compared to placebo. Tocilizumab and rituximab were also superior to azathioprine 
in head-to-head studies. Rituximab, tocilizumab and to some extent eculizumab have well-known safety profiles for other 
inflammatory diseases, and rituximab and azathioprine may be safe during pregnancy.
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Introduction
Neuromyelitis optica (NMO) was previously characterized 
by bilateral optic neuritis and transverse myelitis. After the 
discovery of antibodies against aquaporin 4 (AQP4-IgG), 
it was acknowledged that clinical presentation can be more 
diverse, and the term NMO spectrum disorder (NMOSD) 
was introduced in 2007 [1]. In 2015, the International Panel 
for NMO Diagnosis decided to only use this unifying term 
[2]. In patients with AQP4-IgG, the diagnosis only requires 
one of the six core clinical criteria including optic neuri-
tis and acute myelitis. In patients without AQP-4 IgG, it 
requires two core clinical characteristics disseminated in 
space, and at least one of these must be myelitis, optic neuri-
tis, or area postrema syndrome supported by MRI [2]. Some 
AQP4-IgG-negative NMOSD patients may have antibodies 
against myelin oligodendrocyte glycoprotein (MOG-IgG). 
MOG-IgG-associated disease (MOGAD) is increasingly 
recognized as a distinct entity [3, 4], characterized by optic 
neuritis, transverse myelitis and/or brain stem syndrome in 
combination with positive MOG-IgG [5]. NMOSD with 
AQP4-IgG is rarely monophasic, attacks are often severe, 
and up to 25% have other autoimmune disease [6].
Several treatments that are effective in multiple sclerosis 
(MS), including interferon beta, fingolimod, alemtuzumab 
and natalizumab are associated with severe outcome includ-
ing catastrophic exacerbations in patients with NMOSD 
[7–9].
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Treatment of NMOSD has been based on case series 
and consensus reports [10]. Very recently, the results of six 
randomized clinical trials with five monoclonal antibod-
ies (Table 1) targeting four different molecules and three 
pathways (Fig. 1) have been published [11–16]. We here 
review existing and emerging NMOSD treatments about 
to be implemented in clinical practice. Experimental treat-
ments were recently reviewed elsewhere [17]. AQP4-IgG 
is expressed on the placenta, and expecting mothers with 
NMOSD have high risk of miscarriage, pre-eclampsia and 
eclampsia, particularly if untreated or unstable [18–20]. 
The relapse risk during pregnancy and particularly post-
partum is also high [21–24]. Compatibility with pregnancy 
is, therefore, important in treatment decisions and will be 
highlighted in this paper.
Traditional immunosuppressive treatment
Traditional immunosuppressive treatment, including aza-
thioprine or mycophenolate mofetil in combination with 
low-dose corticosteroids has been a cornerstone in treat-
ment of NMOSD, and is still widely used [25]. The use of 
low-dose corticosteroids for maintenance treatment is sup-
ported by retrospective evidence [26], but has not been stud-
ied systematically.
Azathioprine is a prodrug of 6-mercaptopurine, which 
inhibits purine synthesis and lymphocyte proliferation [27]. 
Positive results in NMOSD were first reported in 1998 in 
a prospective study of seven patients followed for at least 
18 months [28]. Mean Expanded Disability Status Scale 
(EDSS) score improved from 9.0 to 3.0, and no relapses 
occurred.
Table 1  Major randomized clinical trials
ARR Annualized relapse rate, AZA azathioprine, EDSS expanded disability status scale, MMF mycophenolate mofetil
a New primary endpoint based on adjudicated relapses. ARR based on physician-determined (non-adjudicated) relapses was 0.24 (p < 0.001)
b At baseline. All patients had previously tested positive for AQP4-IgG
c Azathioprine or mycophenolate mofetil and rituximab
d Azathioprine or mycophenolate mofetil
RIN-1 N-MOmentum TANGO SAkuraStar SAkuraSky Prevent
Target CD20 CD19 IL6R IL6R IL6R C5












Design Double-blind Double-blind Open Double-blind Double-blind Double-blind
Randomisation ratio 1:1 3:1 1:1 2:1 1:1 2:1
Trial duration 72 weeks Up to 197 days 60 weeks 96 weeks 96 weeks 91 weeks
Administration iv iv Iv/oral sc sc iv
Baseline characteristics in the active arm
 Age (years; mean) 53 43.2 48.1 45.3 40.8 43.9
 Number 19 174 analyzed 55 63 41 96
 Female (%) 90 94 93 73 90 92
 ARR 1.4 ≥ 1 1.71 1.4 1.5 1.94
 EDSS score 
(mean)
3.5 4.4 4.5 3.9 3.83 4.0
 AQP4-IgG (%) 74b 87% 85 65 66 100%
 Maintenance 
 therapyc
Not reported 67% 98% 100% 58% 66%
Co-treatment in the active arm in study period
 Maintenance 
 therapyd
None None Only first 12 weeks None Continued Continued 
unless safety 
concerns
 Prednisolone (%) Reduced to 2 mg/
day
All patients until 
day 21
Only rescue therapy Only rescue therapy 41 17
Outcome (active vs comparator)
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Most evidences on azathioprine in NMOSD come from 
retrospective case series. Of 99 patients treated until 2009 at 
the Mayo Clinic, 38 discontinued treatment due to adverse 
events or disease activity [29]. In the remaining 61 patients, 
annualized relapse rate (ARR) fell from 1.5 to 0.2, and 26 
became relapse-free. The failure rate for azathioprine was 
later reported to be higher than for rituximab and mycophe-
nolate mofetil [30]. In 36 patients from Sao Paulo, mean 
ARR fell from 5.0 to 1.0 after treatment [31]. Of 100 Bra-
zilian patients followed for median seven years, 69 had no 
disability progression but 11 discontinued treatment due 
to side effects [32]. Similar results were reported for 28 
Iranian patients [33]. Of 103 AQP4-IgG-positive patients 
from UK, 63 remained relapse-free for a median follow-up 
of 18 months. Azathioprine was, however, discontinued in 
47 patients, mostly because of side effects [34].
Recently, azathioprine was shown inferior to rituximab 
and tocilizumab on relapses and disability progression in 
head-to-head studies [11, 16], supporting previous case 
series and one open clinical trial indicating that azathioprine 
may be inferior to rituximab and mycophenolate mofetil [30, 
35–38].
Azathioprine is transferred through placenta, but because 
the fetus lacks the enzyme generating active metabolites, 
concentrations of these are lower than in the mother [39, 40]. 
A recent expert recommendation emphasized that the num-
ber of exposed pregnancies exceeds 2000, and that azathio-
prine might be relatively safe during pregnancy [22]. Two 
large retrospective studies did, however, suggest increased 
risk of preterm birth and low birthweight [41, 42], and pos-
sibly also cardiac septal defects [42]. Another large study 
did not confirm this [43]. Bone marrow suppression in the 
infant may occur [44], and regular laboratory testing and 
ultrasound screening are necessary to evaluate fetal growth, 
organ development, and need of dose reduction [22]. The 
active drug is largely absent in breast milk (the maximum 
exposure of the drug to the infant is < 1% of the maternal 
dose) and blood of the infant [45, 46]. Breastfeeding is pos-
sible, although asymptomatic neutropenia has been reported 
[47]. The American College of Rheumatology strongly rec-
ommends continuing azathioprine during pregnancy and 
conditionally recommends during breastfeeding (118).
Mycophenolate mofetil is a reversible inhibitor of inosine 
monophosphate dehydrogenase, which is involved in guano-
sine nucleotide synthesis needed for lymphocyte prolifera-
tion [48]. In 2006, it was reported that a girl with NMO had 
been treated successfully with mycophenolate for two years 
[49]. The drug has later been increasingly used in NMOSD, 
and the first retrospective study was published in 2009 [50]. 
In 24 patients followed at the Mayo Clinic for a median of 
28 months, median ARR fell from 1.3 to 0.09, and disability 
stabilized or decreased in 22 patients. Among 28 patients 
treated at the Mayo Clinic and the Johns Hopkins Hospital, 
failure rate (36%) was similar to that of rituximab and better 
than for azathioprine [30]. Corroborating these results, 36 
of 62 Chinese patients remained relapse-free for a median 
of 1.5 years [51]. Case series and a meta-analysis indicate 
that the efficacy of mycophenolate mofetil is comparable to 
rituximab, and mycophenolate mofetil was also most toler-
able in meta-analysis [36, 37].
Methotrexate is a folate derivative that inhibits nucleotide 
synthesis. In a retrospective study of 14 AQP4-IgG seroposi-
tive patients followed for a median of 21.5 months, median 
ARR decreased from 1.4 to 0.2, and 43% of the patients 
became relapse-free [52]. Disability stabilised or improved 
in 79%, and no patients stopped treatment due to adverse 
effects. In another nine patients, mean ARR dropped from 
3.1 to 1.1 after treatment.[53].
Mitoxantrone intercalates into DNA causing crosslinks 
and strand breaks. In 2006, it was reported that five patients 
followed prospectively for two years had two relapses [54]. 
In 20 patients treated up to a cumulative dose of 120 mg/m2 
and followed for a mean of 41 months, relapse rate decreased 
by 75% and disability improved or stabilized in all patients 
[55].
Cyclophosphamide is an alkylating agent that cross-
links guanine bases in DNA. In four AQP4-IgG-positive 
patients, EDSS improved from 8.0 to 5.74 after treatment 
[56]. In another retrospective cohort of 41 patients treated 
for a median of 13.6 months, median ARR dropped from 0.7 
to 0.0 [57]. Reports are, however, conflicting. Thus, six of 
seven patients treated with pulse doses of cyclophosphamide 
at the Federal University of São Paulo continued to have 
relapses from which one died [58].
Cyclosporine A is a natural immunosuppressant iso-
lated from the fungus Beauveria nivea. In nine AQP4-IgG-
positive patients NMOSD treated up to 51 months, ARR 
decreased from 2.7 to 0.4 [59].
Methotrexate, mitoxantrone, cyclophosphamide and 
mycophenolate mofetil are teratogenic [60–62], and should 
if possible be avoided in fertile women with NMOSD.
Autologous hematological stem cell 
transplantation (HSCT)
HSCT has not been extensively used in NMOSD, and results 
may depend on the conditioning regime. Thus, of 16 patients 
with refractory disease receiving different conditioning regi-
mens comprising either intermediate-intensity myeloabla-
tive conditioning with carmustine, etoposide, cytarabine and 
melphalan (BEAM) plus anti-thymocyte globulin (ATG, 
n = 9) or low-intensity non-myeloablative regimen with 
thiotepa-cyclophosphamide (n = 3) cyclophosphamide and 
ATG (n = 4), only three patients remained relapse-free and 
13 had relapse or progression in disability after a median 
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of 47 months [63]. More encouraging results have been 
reported for non-myeloablative cyclophosphamide, ATG and 
rituximab conditioning [64]. In a prospective study, 80% 
of 12 patients treated with this non-myeloablative regime 
remained relapse-free without any other immunomodulatory 
treatment after a median of 57 months, and most patients 
also became AQP-IgG seronegative [65].
Interleukin 6 (IL‑6) pathway inhibitors
The pro-inflammatory cytokine IL-6 was identified as a B 
cell stimulator in 1986. IL-6 is produced by several cell 
types including monocytes, macrophages and lympho-
cytes, and regulates the expression of proteins involved 
in inflammation, immune responses, and cell differentia-
tion and homeostasis [66]. The IL-6 receptor (IL-6R) is 
expressed on the membrane of hepatocytes and leukocytes 
(mIL-6R), and as soluble forms (sIL-6R) in the circulation 
[66]. Both mIL-6R and sIL-6R transduce IL-6 signaling 
through glycoprotein 130 (gp130) which is ubiquitously 
expressed on hematopoietic and non-hematopoietic cells 
[67]. Classic signaling through mIL-6R induces anti-
inflammatory responses, such as differentiation from M1 to 
M2 macrophages, while binding of sIL-6R/IL-6 to gp130 
(trans-signaling) induces pro-inflammatory responses [66, 
68]. In a third signaling pathway (trans-presentation), den-
dritic cells present mIL-6R/IL-6 to naïve T cells during 
differentiation into Th17 cells [69]. AQP4-specific Th17 
cells are frequent in the blood of patients with NMOSD 
[70], and Th17 cells play an important role in the patho-
genesis [71] (Fig. 1).
IL-6 levels are elevated in blood and cerebrospinal fluid 
of NMOSD patients and correlate with AQP4-IgG levels and 
disease severity [72, 73]. IL-6 facilitates disruption of the 
blood–brain barrier and enhances lesion severity [74, 75], 
and promotes AQP4-IgG production in vitro and ex vivo 
[76].
Tocilizumab was the first humanized monoclonal anti-
body against IL-6R. It is licenced for treatment of rheuma-
toid arthritis, giant cell arteritis and cytokine release syn-
drome, but has not been considered by EMA or FDA for 
NMOSD. Case reports suggest beneficial effects in NMOSD 
on relapses, disability progression, pain, and fatigue [77–80]. 
In 2014, a pilot study with seven NMOSD patients treated 
with intravenous tocilizumab reported a fall in mean ARR 
from 2.9 to 0.4 [81]. In another eight highly active patients 
followed for 10–51 months, median ARR dropped from 
4.0 to 0.4 and median EDSS score from 7.3 to 5.5 [82]. 
Recently, similar results were reported in 12 patients treated 
with subcutaneous tocilizumab [83].
Tocilizumab has been used for 10 years and by more 
than one million rheumatoid arthritis (RA) patients, also in 
combination with methotrexate. The safety profile is, there-
fore, well established [84]. Tocilizumab induces a modest 
increase in lipoproteins and risk of neutropenia and bacte-
rial infections, most markedly in combination with metho-
trexate [85]. This does not seem to increase with treatment 
duration [84, 86]. In the British Society for Rheumatology 
Biologics Register for Rheumatoid Arthritis, the risk of seri-
ous infections tended to be higher for tocilizumab than for 
rituximab [87], whereas an opposite trend appeared in Dan-
ish and Swedish RA registries [88]. So far, neutropenia and 
serious infections seem to be less frequent in NMOSD than 
in RA [77].
TANGO was an open-label, multicentre, randomised, 
phase-2 trial comparing intravenous tocilizumab (8 mg/
kg every 4 weeks) with azathioprine (2–3 mg/kg per day) 
in 118 Chinese patients followed for up to 90 weeks [16] 
(Table 1). Almost all patients used immunosuppressive 
therapy at baseline. Patients randomized to tocilizumab had 
to stop these within 12 weeks. Patients in the azathioprine 
arm used azathioprine as monotherapy from week 24. Those 
who had used azathioprine for less than 24 weeks before 
randomization received supplementary immunosuppressants 
until 24 weeks of azathioprine treatment. Time to relapse 
(primary outcome) was longer in the tocilizumab than in 
the azathioprine group (78.9 vs 56.7 weeks; p = 0.0026). 
Eight (14%) patients on tocilizumab and 28 (47%) on aza-
thioprine had an attack during the study, corresponding to 
a risk reduction of 76% (p < 0.0001). Among the AQP4-
IgG-negative patients, two of nine (22%) on tocilizumab 
Fig. 1  Pathogenesis and drug targets in NMOSD. Aquaporin 4 
(AQP4)-specific B cells mature and differentiate in the periphery to 
memory cells or AQP4-IgG secreting cells (1). T cells may interact 
with B cells or dendritic cells, and upon stimuli including IL-6  T 
cells differentiate to pro-inflammatory Th17 cells that can cross the 
blood brain barrier (2). Inflammatory conditions allow both antibod-
ies and complement factors to traverse the blood brain barrier and 
bind to AQP4 on astrocytic end feet (3). This activates complement 
through C1q ligation leading to formation of C5a and C5b. C5b is 
part of the membrane attack complexes (MAC) (4). C5a recruits pro-
inflammatory leukocytes, including eosinophils, neutrophils, natural 
killer (NK) cells, and macrophages (5), capable of antibody depend-
ent cellular cytotoxicity or inflammatory degranulation through Fc 
receptor activation (6). Astrocytes targeted by these mechanisms 
undergo destruction, and oligodendrocytes and neurons lose their 
supportive functions (7). The IL-6R blockers satralizumab and toci-
lizumab (A) suppress differentiation of AQP-IgG antibody secreting 
cells (ASC), as well as generation of pro-inflammatory Th17 T cells 
and M1 macrophages in favour of regulatory T cells and M2 mac-
rophages. Rituximab (B1) kills cells expressing CD20 (mainly naïve 
and memory B cells, but also some T cells), while inebilizumab (B2) 
depletes a wider proportion of the B cell repertoire expressing CD19, 
including some antibody secreting cells. Both rituximab and inebili-
zumab deplete antigen presenting memory B cells. Eculizumab (C) 
blocks the complement cascade by binding complement component 
5 (C5), halting generation of MAC through C5b and recruitment of 
pro-inflammatory cells through C5a. Printed with permission from © 
Kari C. Toverud
◂
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and three of six (50%) on azathioprine relapsed during the 
study. AQP4-IgG levels dropped by 50% in the tocilizumab 
group and remained unchanged in the azathioprine group. 
Tocilizumab reduced the relative risk of 24 weeks confirmed 
disability progression by 78% compared to azathioprine 
(exploratory analysis).
Overall adverse events were equally frequent, but some 
adverse events were more common in the azathioprine group 
compared to tocilizumab: elevation of alanine transferase 
(31% vs 46%), upper respiratory tract infections (29% vs 
39%), and urinary tract infections (29% vs 36%). There were 
10-grade 3–5 adverse events in the tocilizumab group and 23 
in the azathioprine group. Two patients stopped tocilizumab 
and three patients stopped azathioprine because of adverse 
events. One patient on tocilizumab died from myelitis and 
respiratory failure, and one patient on azathioprine died from 
listeriosis.
The concentration of tocilizumab in cord blood serum of 
an infant was recently reported to be 80–90% of maternal 
concentrations [89]. Prospective (n = 180) and retrospec-
tive (n = 108) data on pregnancies exposed to tocilizumab 
(beyond the first trimester in altogether 17 patients) indi-
cated slightly increased risks of malformation without 
distinct pattern, spontaneous abortion, and preterm birth 
[90]. One-third of the patients with adverse outcomes were, 
however, also treated with methotrexate/leflunomide. No 
evidence of increased risks was found in a Japanese cohort 
of 61 pregnancies including 30 patients who were treated 
during the first trimester [91]. NMOSD experts recently rec-
ommended that tocilizumab can be used during pregnancy 
in patients with very severe NMOSD, and that breastfeed-
ing could be considered under close monitoring [22]. The 
American College of Rheumatology concluded that treat-
ment until conception and breastfeeding during treatment are 
supported by conditional evidence [92]. Drugs and Lactation 
Database recommend particular caution in mothers of pre-
term infants [93].
Satralizumab is modified from tocilizumab through amino 
acid sequence alterations in the CDR domains, variable 
regions, and constant regions. The mutations in the CDR and 
variable regions reduce binding affinity with IL-6R at low 
pH (Fig. 2). Satralizumab, therefore, dissociates from IL-6R 
in the acidic environment found in early endosomes, and is 
excreted rather than being digested [94], allowing extended 
dosage intervals (Fig. 2). Satralizumab is approved for AQP4 
NMOSD by FDA, and decision by EMA is pending.
Subcutaneous satralizumab 120 mg at week 0, 2 and every 
four weeks thereafter, has been tested as monotherapy and 
as add-on therapy in two double-blind placebo-controlled 
phase III trials (SAkuraStar and SAkuraSky), comprising 
altogether 188 patients aged 13–74 years [13, 14] (Table 1). 
In both trials, all reported relapses were evaluated by a clini-
cal endpoint committee (adjudicated relapses).
In SAkuraSky, patients continued using azathioprine 
or mycophenolate mofetil plus oral glucocorticoids, but 
not rituximab [14]. At baseline, 24 of 42 patients on 
Fig. 2  Endosomal processing of tocilizumab and satralizumab. The 
IL-6 receptor (IL6R) is present on a vast array of cells in the immune 
system, and also exists in soluble form in circulation. Membrane 
bound IL-6R (mIL-6R) or the soluble variant (sIL-6R) interacts 
with glycoprotein 130 (gp130) upon ligation with IL-6. Gp130 acts 
as a signal transducer into the cell that regulates expression of pro-
teins involved in inflammation and cell homeostasis. Upon binding to 
mIL-6R, the receptor is brought intracellularly into endosomal com-
partments, where pH drops. Satralizumab, unlike the closely related 
tocilizumab, was specifically engineered with alterations in both 
variable regions to dissociate from IL-6R at low pH, and changes in 
the constant regions to simultaneously maintain affinity for neonatal 
Fc receptors (FcRn). FcRn are present in the endosomes, and allow 
satralizumab to recirculate to the cell surface and re-bind another s/
mIL-6Rs thus enabling extended dosage protocol. Printed with per-
mission from © Kari C. Toverud
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satralizumab and 21 of 41 patients on placebo used either 
azathioprine or mycophenolate mofetil. Adjudicated 
relapses (primary outcome) occurred in eight patients 
(20%) on satralizumab and in 18 (43%) on placebo (rela-
tive risk reduction 62%; p = 0.02). At 96 weeks, 78% of 
patients on satralizumab and 59% on placebo were relapse-
free. The study was negative for AQP4-IgG-seronegative 
patients, as 5 of 14 patients on satralizumab and 6 of 14 
patients on placebo relapsed. The first key secondary 
endpoint, reduction in pain, was negative. The number of 
adverse events and severe adverse events did not differ, 
and there were no deaths. Three patients on satralizumab 
and 10 patients on placebo discontinued the study during 
the double-blind period.
SAkuraStar was a phase-3, placebo-controlled parallel-
group study of satralizumab as monotherapy [13]. Nine-
teen of the 63 patients (30%) receiving satralizumab and 
16 of the 32 (50%) receiving placebo relapsed (HR 0.45, 
p = 0·018). After 96 weeks, 72% of patients on satrali-
zumab and 51% on placebo were relapse-free. Again, the 
effect of satralizumab on ARR was only observed among 
AQP4-IgG-positive patients, as 10 of 22 (46%) patients 
on satralizumab in the AQP4-IgG-seronegative subgroup 
relapsed versus three of nine (33%) on placebo. As in 
SakuraSky, pain was not significantly reduced by satrali-
zumab. Whereas the frequency of serious adverse events 
was quite similar (19% and 16%), severe adverse events 
were more common on satralizumab than on placebo (27% 
vs 6%). These were mostly considered unrelated to the 
study drug and did not lead to discontinuation, unless in 
one case of severe pneumonia in the satralizumab group. 
No deaths occurred in either group. One patient in each 
group withdrew from the study due to adverse events.
Collectively, these three trials provided evidence for 
the efficacy and safety of intravenous and subcutaneous 
anti-IL6R treatment mainly in AQP4-IgG-seropositive 
NMOSD, both as monotherapy and add-on treatment.
Pregnancy outcomes with satralizumab are unknown, 
but considerations may be similar to tocilizumab.
Complement blocking therapy
Complement deposits were early recognized in NMOSD 
lesions [95], and complement markedly enhances the patho-
genicity of AQ4-IgG in vivo and ex vivo [74, 96–98]. Ecu-
lizumab is a monoclonal IgG2 antibody targeting C5, and 
inhibits cleaving and prevents release of pro-inflammatory 
C5a and the involvement of C5b in the membrane attack 
complex [99] (Fig. 3). Eculizumab could, thus, downregu-
late adaptive and innate immune responses either through 
C5a in the periphery, or through C5b on astrocytes in the 
CNS [100] (Figs. 1, 3). Eculizumab has been approved by 
EMA and FDA for AQP4-IgG positive NMOSD, and is 
also licenced for paroxysmal nocturnal hemoglobinuria and 
myasthenia gravis.
In an open-label phase II trial with 14 AQP4-IgG-positive 
NMOSD patients, 12 patients were relapse-free and none 
progressed during twelve months on eculizumab, whereas 
five relapsed within five months after withdrawal [101]. One 
patient had meningococcal sepsis and sterile meningitis dur-
ing the treatment.
Fig. 3  Mechanism of eculizumab. Eculizumab binds complement 
component 5 (C5) and prevents cleavage into C5a and C5b by C5 
convertase. C5a is a potent attractant for leukocytes. C5b can form a 
complex with C6, and form the basis for formation of the membrane 
attack complex (MAC), which includes additional complement com-
ponents. Printed with permission from © Kari C. Toverud
 Journal of Neurology
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PREVENT was a phase III, randomized, double-blind, 
placebo-controlled trial comprising 143 AQP4-IgG-positive 
NMOSD patients randomized 2:1 to eculizumab (900 mg 
weekly for 4 weeks and 1200 mg every 2 weeks thereaf-
ter) or placebo [15] (Table 1). Most (76%) patients contin-
ued their previous immunosuppressive therapy. Forty-six 
patients had previously used rituximab, which was stopped 
within three months before inclusion. Given the uncer-
tainty of when the final relapse would occur, the sponsor 
terminated the trial after 23 of the predefined 24 adjudi-
cated relapses. Three of 96 patients on eculizumab and 20 
of 47 on placebo had adjudicated relapse (primary outcome), 
corresponding to a hazard ratio 0.06 (p < 0.001). None of 
the 34 patients on eculizumab monotherapy experienced 
adjudicated relapses, versus 7 of 13 on placebo. Physician-
determined (non-adjudicated) relapse (original primary 
end point) occurred in 14 patients on eculizumab and 29 on 
placebo (p < 0.001). There was no difference in disability 
progression as measured by EDSS (− 0.18 on eculizumab 
group and 0.12 on placebo). Patients receiving eculizumab 
had higher rates of upper respiratory tract infections and 
headache. There were no pneumococcus infections, but one 
patient on eculizumab and azathioprine died from pulmo-
nary empyema with cultures yielding Peptostreptococcus 
micros and Streptococcus intermedius, which are part of 
the normal microbiota and common causes of opportunistic 
infections [102]. More patients on eculizumab (17%) than 
on placebo (6%) discontinued the study.
Data about eculizumab during pregnancy are available 
in paroxysmal nocturnal hemoglobinuria, atypical hemo-
lytic uremic syndrome, and HELLP syndrome (hemolysis, 
elevated liver enzymes and low platelet levels). In these dis-
eases, higher dose of eculizumab is required during preg-
nancy to block complement activity [103]. Transfer to new-
borns is low [103], and newborns of mothers treated with 
eculizumab have normal complement function [104]. The 
concentrations in breast milk are also low, and eculizumab 
is suggested to be safe during pregnancy and lactation [105]. 
Data are, however, limited [93], and therapeutic concentra-
tion with transient low complement levels in a newborn was 
recently reported [106].
B cell depletion
B cell involvement in NMOSD may include production of 
autoantibodies, T cell activation and cytokine production 
[107] (Fig. 1).
Rituximab targets CD20 and depletes B cell lineage 
cells from late pro-B cells through early plamablasts, and 
also some T cells [108]. During the last 15 years, several 
retrospective case series have reported promising results 
in NMOSD. Rituximab has been included in treatment 
guidelines [109], but has not been reviewed or approved by 
EMA or FDA for this indication. In the first report from 
2005, six of eight patients became relapse-free and seven 
experienced substantial disability improvement [110]. 
In two later retrospective studies on 25 and 23 patients, 
median ARR dropped from 1.7 and 1.9 to 0.0 and disabil-
ity improved or stabilized in most patients [111, 112]. In 
the 10-year material from Johns Hopkins Hospital and the 
Mayo Clinic, rituximab reduced ARR up to 88.2%, and two 
in three patients achieved complete remission [30]. In 30 
patients followed for five years in Korea, ARR fell from 2.4 
to 0.3, 18 patients became relapse-free, and disability either 
improved or stabilized in 28 [113]. In another retrospective 
study of 32 patients treated first-line with rituximab, ARR 
was reduced by 97% [114]. Significant reduction in relapse 
rate was also reported in 16 children followed for a mean of 
6.1 years [115].
In a 1-year open controlled trial comprising 86 patients, 
rituximab was significantly more effective than azathioprine 
[38]. ARR (primary outcome) decreased from 1.0 to 0.5 
in the azathioprine group and from 1.3 to 0.2 in the rituxi-
mab group. Nineteen patients (54%) in the azathioprine 
group and 26 patients (79%) in the rituximab group became 
relapse-free. Patients receiving rituximab also improved sig-
nificantly more in mean EDSS score (0.98 vs 0.44). Results 
were not specified for AQP4-IgG- seropositive and seron-
egative patients. It is, therefore, not known whether the high 
proportion of AQP4-IgG-seronegative patients (60.6% in the 
rituximab arm and 42.9% in the azathioprine arm for per 
protocol analysis) may have influenced the results. Any mis-
classification of MS as seronegative NMOSD could possibly 
have favoured rituximab.
In a randomized double-blind RCT (RIN-1), 19 patients 
were randomized to rituximab 375 mg/m2 weekly for four 
weeks and then 1000 mg every 2 week at week 24 and 48, 
and 19 patients were randomized to placebo [11] (Table 1). 
All patients were previously AQP4-IgG-seropositive, but 11 
were seronegative at baseline. Mean ARR two years before 
inclusion was 1.4 for patients randomized to rituximab and 
0.9 for patients randomized to placebo. Three patients on 
rituximab who discontinued treatment during the 72 weeks 
of follow-up (one withdrew consent, one used contraindi-
cated drug, one had adverse event) were included in the 
primary analysis. Seven relapses occurred in the placebo 
group and none in the rituximab group (p = 0.0058). Change 
in EDSS score did not differ between groups. Eight of the 
11 AQP4-IgG-seronegative patients at baseline became 
positive during the study. AQP4-IgG titers decreased in six 
patients on rituximab but in none of the patients on placebo, 
and increased > 10% in one patient on rituximab and in five 
patients on placebo.
The optimal dosage of rituximab in NMOSD is not deter-
mined. Studies using dosages ranging from 100 mg [116] to 
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1000–2000 mg [117] every 6 month have reported similar 
results. Both in adults and children, disease activity seems 
to correlate with depletion of B cells, but less clearly with 
AQP4-IgG levels [115, 118, 119]. In contrast to MOGAD, 
relapses mainly occur after repopulation of memory B cells 
in blood in AQP4-IgG NMOSD, supporting the effect of 
rituximab in AQP4-IgG-positive NMOSD [120]. Re-dosing 
based on measurements of CD27+ memory B cells may pos-
sibly allow disease control at a lower dose than fixed-dose 
intervals [113, 121].
Inebilizumab is a humanized, monoclonal antibody tar-
geting the B cell surface antigen CD19. In contrast to CD20, 
CD19 is also expressed by pro-B cells, plasmablasts, and 
plasma cells, but not by any T cells. Inebilizumab has been 
studied in preclinical models [122] and was reported safe in 
phase-1 clinical studies of systemic sclerosis [123] and mul-
tiple sclerosis [124]. Inebiluzumab was approved by FDA 
for AQP4-IgG NMOSD June 2020, and has been granted 
orphan designation by EMA.
N-MOmentum was a double-blind phase-2/3 study 
comprising 231 patients randomized (3:1) to inebilizumab 
or placebo as monotherapy [12] (Table 1). The patients 
received intravenous inebilizumab (total dose 600 mg) or 
placebo on days 1 and 15, with no further doses. Two-thirds 
of the patients had used other immunosuppressants previ-
ously. Cyclophosphamide. Methotrexate, cyclosporine and 
mitoxantrone had to be stopped at least three months prior 
to randomization, and no other immunosupressants were 
allowed during the study. To minimize the risk of an attack 
following withdrawal of previous treatment and initiation 
of inebilizumab, all participants received oral prednisone 
20 mg per day or equivalent from day one tapered to day 21. 
The double-blinded period lasted up to 197 days, or to a new 
NMOSD attack or termination of enrolment. All patients 
were thereafter offered open-label therapy.
Because of a clear demonstration of efficacy, enrolment 
was stopped before reaching the target of 252 patients and 
67 adjudicated attacks. A total of 169 of 175 patients on 
inebilizumab and 54 of 56 patients on placebo completed 
the study period. Inebilizumab significantly increased time 
to onset of a new attack compared with placebo (p < 0.0001). 
In intention-to-treat analyses, 21 of 174 patients on inebi-
lizumab experienced an attack versus 22 of 56 on placebo 
(hazard ratio 0.27, p < 0.0001). Among the 17 AQP4-IgG-
seronegative patients, attacks were recorded in three of 13 
on inebilizumab and none of four on placebo. Fewer patients 
had EDSS worsening on inebilizumab compared to pla-
cebo (p = 0.0049). No differences in change in low-contrast 
visual acuity binocular score from baseline were detected, 
but significantly fewer inebilizumab-treated patients expe-
rienced optic neuritis compared to placebo (10 patients 
in each group, corresponding to HR 0.288). Patients on 
inebilizumab  had fewer new MRI lesions (p = 0.0034) and 
hospitalizations (p = 0.010) compared to placebo.
Adverse events, serious adverse events, infusion reac-
tions and infections were equally frequent among patients 
on inebilizumab and on placebo, and no malignancies were 
reported. No death occurred during the placebo-controlled 
phase, but two patients died during the open-label phase, 
one (originally receiving placebo) because of respiratory 
insufficiency due to the ongoing disease process. Another 
patient (originally receiving inebilizumab) developed new 
neurological symptoms including seizures nine days after 
receiving 300 mg inebilizumab in the open-label period. 
MRI showed new large lesions in white and grey matter, 
considered not representative for progressive multifocal leu-
koencephalopathy (PML). PCR for John Cunningham virus 
in cerebrospinal fluid were negative in two laboratories but 
positive in another. No definitive diagnosis was made, and it 
could not be excluded that the death was treatment-related.
Monoclonal antibodies are not transported to the fetus 
until the second trimester [125]. Given their prolonged effect 
on B cells and half-life around three weeks [126], rituximab 
and inebiluzumab administered before conception may pro-
tect the mother against relapses without exposing the fetus 
to potential harmful effects. Data from 153 pregnancies in 
mothers treated with rituximab for hematological malignan-
cies and autoimmune diseases, including 21 treated during 
pregnancy, indicated increased risk of miscarriage and pre-
mature birth [127]. Many of these mothers had, however, 
also used other immunosuppressants. Limited data in MS 
and NMOSD do not suggest increased risk of adverse preg-
nancy outcomes beyond reversible hematological abnor-
malities [128, 129], also in those very few treated during 
pregnancy [129, 130]. Both the American College of Rheu-
matology and NMOSD experts conditionally recommend 
rituximab until conception, and if necessary also during 
pregnancy [22, 92]. B cells should be measured in the infant, 
and vaccination planned accordingly.
Rituximab concentrations in breast milk are low, and 
rituximab is likely not absorbed from the gastrointestinal 
tract [131, 132]. The American College of Rheumatology 
recently concluded that recommending breastfeeding during 
treatment with rituximab is supported by strong evidence 
[92]. Drugs and Lactation Database recommend caution, 
particularly in preterm infants [133].
Pregnancy outcomes with inebilizumab are unknown, but 
considerations may be similar to anti-CD20 therapy.
Discussion
Differences in study design (active comparator versus pla-
cebo, monotherapy versus add-on therapy, open versus 
blinded) preclude conclusions on the relative efficacy of the 
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monoclonal antibodies in NMOSD. Patients in the RIN-1 
study of rituximab, N-MOmentum  of inebiluzumab and 
SakuraSTAR of satralizumab had to stop ongoing immu-
nosuppressive treatment [11–13]. The use of prednisolone 
was also restricted in these studies and in the TANGO study 
of tocilizumab (Table 1). It is, therefore, conceivable that 
control patients in these studies had poorer outcome than 
they would have had in routine practice [134]. On the other 
hand, co-treatment with immunosupressants that has not 
been proven effective in randomized trials may possibly 
have confounded the results of the PREVENT study of ecu-
lizumab and the SAkuraSky study of satralizumab [100]. It 
is, therefore, reassuring that satralizumab was superior to 
placebo also as monotherapy [13], and that rituximab and 
tocilizumab were more effective than azathioprine [16, 38]. 
Data on de novo treatment are scarce in NMOSD, particu-
larly for the novel drugs, as all or more than two-thirds of the 
patients in the recent clinical trials had used other immuno-
suppressants at enrolment.
The robust treatment responses to eculizumab and to 
satralizumab monotherapy compared to placebo prove that 
IL-6 signaling and complement activation are relevant ther-
apeutic targets in NMOSD patients with AQP4-IgG, who 
have the highest risk of relapse [135]. The effect of these 
novel treatment options is, however, less clear for patients 
without AQP4-IgG. Eculizumab was only tested in AQP4-
IgG-positive patients [15], and the effect of satralizumab was 
not convincingly shown in seronegative patients [13, 14].
In MS patients, inebilizumab induced a 10.5% decrease 
in total immunoglobulin levels after 24 weeks and 15.0% 
after 18 months [126], exceeding that recorded for rituximab 
[136].
It could be speculated that the broader depletion of the 
B cell linage by inebilizumab, including antibody secreting 
cells, could be an advantage compared to rituximab [134]. 
Although theoretically appealing in an autoantibody-medi-
ated disease, this remains to be proven. More pronounced 
drop in immunoglobulins may also lead to more infections.
Anti-drug antibodies may reduce therapeutic effects 
and can also cause adverse reactions through formation of 
immune complexes. This is particularly relevant for B cell 
therapies, as rituximab is a chimeric, whereas inebilizumab 
is a humanized antibody. Whereas no data exist in NMOSD, 
about one-third of MS patients develop antibodies against 
rituximab [137]. The clinical effect of such antibodies is 
not firmly established. They are, however, associated with 
poorer B cell depletion [137], which likely is unfavorable 
in NMOSD [118, 119], and may rarely also cause serum 
sickness [138]. The immunogenicity of inebilizumab seems 
much lower. Anti-inebilizumab antibodies were measurable 
in only 3% of NMOSD patients on inebilizumab, which was 
not more frequent than in patients on placebo [12]. Anti-drug 
antibodies are rare in rheumatoid arthritis patients treated 
with tocilizumab [139]. It is not known whether modifica-
tions have increased the immunogenicity of satralizumab.
Complement blocking increases the risk of meningococ-
cal and encapsulated bacterial infection [140–142]. There-
fore, patients in PREVENT and also the REGAIN study of 
eculizumab in myasthenia gravis were vaccinated against 
Neisseria meningitidis, and meningitis was not reported in 
either study [143]. Long-term treatment with rituximab and 
possibly also tocilizumab and satralizumab are also associ-
ated with infection risk [144, 145], and pneumococcal vac-
cination is often recommended before starting rituximab. 
Vaccination may, however, increase relapse risk in untreated 
NMOSD patients [146]. On the other hand, eculizumab, 
rituximab and most likely also inebilizumab reduce vac-
cine responses [142, 147]. Whether or not to start treatment 
before vaccination must be based on individual evaluation 
of infection and relapse risk.
Conclusion
The therapeutic armamentarium for NMOSD has expanded, 
and now includes evidence-based oral, subcutaneous and 
intravenous medications given daily, biweekly, monthly 
and every 6 months. The efficacy of monoclonal antibod-
ies in NMOSD-IgG-positive patients is better documented, 
including class I evidence for eculizumab, inebilizumab and 
satralizumab, and likely also greater than traditional immu-
nosuppressive therapy with azathioprine. Based on current 
evidence, we suggest that most NMOSD patients, particu-
larly those with AQP4-IgG, should start with one of the 
monoclonal antibodies as a first-line treatment. Currently, 
we do not know which of these offers the best efficacy. Thus, 
treatment decisions will depend on factors like availabil-
ity, price, co-morbidity and future pregnancy planning. For 
women who might become pregnant, rituximab has the best 
documented and possibly also most favorable safety profile, 
but azathioprine and some other monoclonal antibodies may 
also be compatible with pregnancy in selected patients.
Given the rarity of NMOSD, head-to-head studies of the 
monoclonal antibodies will not likely be conducted. Regis-
try-based follow-up and real-life life studies will hopefully 
clarify optimal sequencing and combination, and particularly 
for B cell depleting drugs also long-term dosing regimens.
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